@article{eaab746174414c188405af77cdd4962f,
title = "Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)",
abstract = "Craig B. Thompson's conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below. CBT is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories.",
author = "McKenney, {Anna Sophia} and Lau, {Allison N.} and Somasundara, {Amritha Varshini Hanasoge} and Barbara Spitzer and Intlekofer, {Andrew M.} and Jihae Ahn and Kaitlyn Shank and Rapaport, {Franck T.} and Patel, {Minal A.} and Efthymia Papalexi and Shih, {Alan H.} and April Chiu and Elizaveta Freinkman and Akbay, {Esra A.} and Mya Steadman and Raj Nagaraja and Katharine Yen and Julie Teruya-Feldstein and Wong, {Kwok Kin} and Raajit Rampal and {Vander Heiden}, {Matthew G.} and Thompson, {Craig B.} and Levine, {Ross L.}",
note = "Publisher Copyright: {\textcopyright} 2018 American Society for Clinical Investigation. All rights reserved.",
year = "2018",
month = oct,
day = "1",
doi = "10.1172/JCI124920",
language = "English",
volume = "128",
pages = "4743",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "American Society for Clinical Investigation",
number = "10",
}